Top

Published in:

01-07-2005 | A.J. Raimondi ISPN Award

Cytotoxicity of rat marrow stromal cells against malignant glioma cells

Authors: Seok-Gu Kang, Sin Soo Jeun, Jung Yeon Lim, Do Sung Yoo, Pil Woo Huh, Kyung Souk Cho, Dal Soo Kim, Hyung-Jin Shin, Jong Hyun Kim, Moon Chan Kim, Joon Ki Kang

Published in: Child's Nervous System | Issue 7/2005

Abstract

Objects

Marrow stromal cells (MSCs) have been shown to have the capacity of orthodox and unorthodox plasticity. In this study, the authors tried to access in vitro cytotoxicity of MSCs from rat and also to differentiate MSCs into immune effector cell.

Methods

Rat MSCs (rMSCs) were isolated by standard methodology and were activated by interleukin-2 (IL-2), interleukin-15 (IL-15), granulocyte macrophage colony stimulating factor, and combinations, which were effector cells. Cytotoxicity of rMSCs and activated rMSCs against the target cells (9L rat glioma cell line) was estimated using visual survival cell assay. Phenotypes of these various activated cells were determined using flow cytometry. The secreted protein from effector cells was estimated by enzyme-linked immunosorbent assay. The expression of immune response-related genes in activated cells was measured.

Results

There was a significant cytotoxicity of rMSCs activated with various cytokine combinations. After various cytokine activations of rMSCs, the population of immune effector cells (CD8, CD161a) and immune reaction-related proteins (IL-4, γ-INF) might increase. Apoptosis may be one of the lysis mechanisms of target cells by activated rMSCs. The contributing genes could be γ-INF, FasL, and perforin.

Conclusion

This study suggests that rMSC may be used as adoptive transfer therapy in patients suffering from malignant brain tumor, but we have to investigate orthotopic animal study for the proper translation.

Kalifa C, Valteau D, Pizer B, Vassal G, Grill J, Hartmann O (1999) High-dose chemotherapy in childhood brain tumours. Childs Nerv Syst 15:498–505CrossRefPubMed

Huncharek M, Wheeler L, McGarry R, Geschwind JF (1999) Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review. Anticancer Res 19:3569–3574

Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, Sanford RA, Kun LE (1997) Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 80:497–504

Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89:52–59PubMed

Johnson JH Jr, Phillips PC (1996) Malignant gliomas in children. Cancer Investig 14:609–621

Barker FG II, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB (1996) Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:442–448PubMed

Wolff JE, Gnekow AK, Kortmann RD, Pietsch T, Urban C, Graf N, Kuhl J (2002) Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94:264–271

Parney IF, Hao C, Petruk KC (2000) Glioma immunology and immunotherapy. Neurosurgery 46:778–791; discussion 791–772CrossRefPubMed

Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci U S A 93:10399–10404CrossRefPubMed

10.

Soling A, Rainov NG (2001) Dendritic cell therapy of primary brain tumors. Mol Med 7:659–667PubMed

11.

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840–852

12.

Tsuboi K, Saijo K, Ishikawa E, Tsurushima H, Takano S, Morishita Y, Ohno T (2003) Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 9:3294–3302PubMed

13.

Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, Saijo K, Ohno T (1999) Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res 90:536–545

14.

Kang SG, Ryu CH, Jeun SS, Park CK, Shin HJ, Kim JH, Kim MC, Kang JK (2004) Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood. Childs Nerv Syst 20:154–162CrossRefPubMed

15.

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897PubMed

16.

Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA et al (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632PubMed

17.

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807CrossRefPubMed

18.

Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS (2004) Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10:1146–1151PubMed

19.

Nagaraj S, Ziske C, Schmidt-Wolf IG (2004) Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther 2:12CrossRefPubMed

20.

Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG (1997) Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74:51–56CrossRefPubMed

21.

Linn YC, Hui KM (2003) Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 44:1457–1462CrossRefPubMed

22.

Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM (2002) Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8:464–468PubMed

23.

Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116:78–86CrossRefPubMed

24.

Morse MA, Clay TM, Lyerly HK (2002) Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther 2:237–247CrossRefPubMed

25.

Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS (2001) A new method for in vitro expansion of cytotoxic human CD3–CD56+ natural killer cells. Hum Immunol 62:1092–1098CrossRefPubMed

26.

Abbas AK, Lichtman AH, Pober JS (2000) Cellular and molecular immunology, 4th edn. Saunders, Philadelphia

27.

Weissman IL (2000) Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 287:1442–1446CrossRefPubMed

28.

Weissman IL (2000) Stem cells: units of development, units of regeneration, and units in evolution. Cell 100:157–168PubMed

29.

Fuchs E, Segre JA (2000) Stem cells: a new lease on life. Cell 100:143–155CrossRefPubMed

30.

Friedenstein AJ (1976) Precursor cells of mechanocytes. Int Rev Cytol 47:327–359PubMed

31.

Kadiyala S, Young RG, Thiede MA, Bruder SP (1997) Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant 6:125–134CrossRefPubMed

32.

Barry FP (2003) Biology and clinical applications of mesenchymal stem cells. Birth Defects Res, C Embryo Today 69:250–256

33.

Short B, Brouard N, Occhiodoro-Scott T, Ramakrishnan A, Simmons PJ (2003) Mesenchymal stem cells. Arch Med Res 34:565–571CrossRefPubMed

34.

Friedenstein AJ, Piatetzky S II, Petrakova KV (1966) Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 16:381–390PubMed

35.

Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL (1998) Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 176:57–66CrossRefPubMed

36.

Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98:10344–10349CrossRefPubMed

37.

Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410:701–705CrossRefPubMed

38.

Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697–705PubMed

39.

Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP (1999) Bone marrow as a potential source of hepatic oval cells. Science 284:1168–1170CrossRefPubMed

40.

Woodbury D, Reynolds K, Black IB (2002) Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 69:908–917CrossRefPubMed

41.

Woodbury D, Schwarz EJ, Prockop DJ, Black IB (2000) Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61:364–370CrossRefPubMed

42.

Sanchez-Ramos JR (2002) Neural cells derived from adult bone marrow and umbilical cord blood. J Neurosci Res 69:880–893CrossRefPubMed

43.

Azizi SA, Stokes D, Augelli BJ, DiGirolamo C, Prockop DJ (1998) Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats—similarities to astrocyte grafts. Proc Natl Acad Sci U S A 95:3908–3913CrossRefPubMed

44.

Brazelton TR, Rossi FM, Keshet GI, Blau HM (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290:1775–1779CrossRefPubMed

45.

Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ (2001) Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105:369–377CrossRefPubMed

46.

Bianco P, Cossu G (1999) Uno, nessuno e centomila: searching for the identity of mesodermal progenitors. Exp Cell Res 251:257–263CrossRefPubMed

47.

Anderson DJ, Gage FH, Weissman IL (2001) Can stem cells cross lineage boundaries? Nat Med 7:393–395CrossRefPubMed

48.

Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M (2000) Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6:1229–1234CrossRefPubMed

49.

Kumagai N, Fukuda K, Ishimura Y, Nishida T (2000) Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13. Investig Ophthalmol Vis Sci 41:1448–1453

50.

Hombauer H, Minguell JJ (2000) Selective interactions between epithelial tumour cells and bone marrow mesenchymal stem cells. Br J Cancer 82:1290–1296CrossRefPubMed

51.

Maestroni GJ, Hertens E, Galli P (1999) Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 55:663–667CrossRefPubMed

52.

Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11:1155–1164CrossRefPubMed

53.

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42–48CrossRefPubMed

54.

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843CrossRefPubMed

55.

Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722–3729CrossRefPubMed

56.

Kim DW, Chung YJ, Kim TG, Kim YL, Oh IH (2004) Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood 103:1941–1948CrossRefPubMed

57.

El-Badri NS, Maheshwari A, Sanberg PR (2004) Mesenchymal stem cells in autoimmune disease. Stem Cells Dev 13:463–472CrossRefPubMed

58.

Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62:5657–5663

59.

Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JS (2002) Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 62:7170–7174

60.

Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97:12846–12851CrossRefPubMed

61.

Stagg J, Lejeune L, Paquin A, Galipeau J (2004) Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 15:597–608CrossRefPubMed

62.

Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603–3608

63.

Simard AR, Rivest S (2004) Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J 18:998–1000PubMed

64.

Bhagwati SN (1989) Treatment of glioma with intratumoral instillation of autologous lymphocytes. Childs Nerv Syst 5:38–40CrossRefPubMed

65.

Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C (2001) Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol/Hematol 39:31–42CrossRef

66.

Naganuma H, Sasaki A, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H (1997) Long-term survival in a young patient with anaplastic glioma. Brain Tumor Pathol 14:71–74PubMed

67.

Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J, Fujimiya Y (1998) Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients. Cancer Immunol Immunother 47:97–103

68.

Franzen R, Bouhy D, Schoenen J (2004) Nervous system injury: focus on the inflammatory cytokine ‘granulocyte-macrophage colony stimulating factor’. Neurosci Lett 361:76–78CrossRefPubMed

69.

Jean WC, Spellman SR, Wallenfriedman MA, Flores CT, Kurtz BP, Hall WA, Low WC (2004) Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J Neuro-oncol 66:39–49CrossRef

70.

Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M (2002) Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 59:514–523PubMed

71.

Kimura S, Yoshino A, Katayama Y, Watanabe T, Fukushima T (2002) Growth control of C6 glioma in vivo by nerve growth factor. J Neuro-oncol 59:199–205CrossRef

Title: Cytotoxicity of rat marrow stromal cells against malignant glioma cells
Authors: Seok-Gu Kang
Sin Soo Jeun
Jung Yeon Lim
Do Sung Yoo
Pil Woo Huh
Kyung Souk Cho
Dal Soo Kim
Hyung-Jin Shin
Jong Hyun Kim
Moon Chan Kim
Joon Ki Kang
Publication date: 01-07-2005
Publisher: Springer-Verlag
Published in: Child's Nervous System / Issue 7/2005
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-005-1216-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cytotoxicity of rat marrow stromal cells against malignant glioma cells

Abstract

Objects

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objects

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2005

Looking at hydrocephalus: where are we now, where are we going?

July 2005

Inner calvarial erosion from traumatic subdural haematoma in infancy

Gargoyles

Air encephalography for hydrocephalus in the era of neuroendoscopy

Influence of the shunt type in the difference in reduction of volume between the two lateral ventricles in shunted hydrocephalic children